We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+20.07%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$530M
AUM Growth
-$28.3M
Cap. Flow
-$54.8M
Cap. Flow %
-10.35%
Top 10 Hldgs %
67.2%
Holding
99
New
35
Increased
16
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$5.65M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$5.31M
3
VRAY
ViewRay, Inc.
VRAY
+$4.67M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$4.21M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.69M

Top Sells

Rank Stock Value
1
DBVT
DBV Technologies
DBVT
+$8.15M
2
FOLD
Amicus Therapeutics
FOLD
+$3.52M
3
NVTA
Invitae Corporation
NVTA
+$3.37M
4
FBRX icon
Forte Biosciences
FBRX
+$3.13M
5
PDSB icon
PDS Biotechnology
PDSB
+$3.11M

Sector Composition

Rank Sector Weight
1 Healthcare 51.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EDIT icon
51
PUT
Editas Medicine
EDIT
$407M
$1.23M 0.23%
+40,000
New +$1.01M
NEOS
52
CALL
DELISTED
Neos Therapeutics, Inc
NEOS
$1.18M 0.22%
+115,500
New +$1.11M
FPRX
53
PUT
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.15M 0.22%
+52,500
New +$1.69M
VRAY
54
CALL
DELISTED
ViewRay, Inc.
VRAY
$1.11M 0.21%
+120,000
New +$961K
MDCO
55
CALL
DELISTED
Medicines Co
MDCO
$1.09M 0.21%
+40,000
New +$1.23M
IMDZ
56
DELISTED
Immune Design Corp.
IMDZ
$1.07M 0.2%
+274,100
New +$1.49M
ATRA icon
57
PUT
Atara Biotherapeutics
ATRA
$77M
$996K 0.19%
+2,200
New +$812K
GKOS icon
58
PUT
Glaukos
GKOS
$10.1B
$795K 0.15%
31,000
+1,000
+3% +$29.8K
EVTC icon
59
PUT
Evertec
EVTC
$1.92B
$751K 0.14%
55,000
-13,800
-20% -$195K
MNTA
60
CALL
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$646K 0.12%
+46,300
New +$626K
FOLD
61
DELISTED
Amicus Therapeutics
FOLD
$632K 0.12%
43,900
-256,100
-85% -$3.52M
MDXG icon
62
PUT
MiMedx Group
MDXG
$622M
$631K 0.12%
50,000
-20,000
-29% -$244K
ONCE
63
PUT
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$514K 0.1%
+10,000
New +$718K
EVH icon
64
CALL
Evolent Health
EVH
$353M
$400K 0.08%
32,500
-50,500
-61% -$712K
MNKD icon
65
PUT
MannKind Corp
MNKD
$1.17B
$400K 0.08%
172,500
-177,500
-51% -$606K
AVEO
66
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$347K 0.07%
+12,434
New +$386K
LXRX icon
67
PUT
Lexicon Pharmaceuticals
LXRX
$1.03B
$321K 0.06%
32,500
-7,500
-19% -$77.9K
NEOS
68
PUT
DELISTED
Neos Therapeutics, Inc
NEOS
$255K 0.05%
+25,000
New +$240K
ASXC
69
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
$203K 0.04%
+8,077
New +$249K
IOVA icon
70
CALL
Iovance Biotherapeutics
IOVA
$1.93B
$88K 0.02%
+11,000
New +$88.3K
TGTX icon
71
CALL
TG Therapeutics
TGTX
$7.07B
$82K 0.02%
+10,000
New +$87.4K
OTLK icon
72
Outlook Therapeutics
OTLK
$171M
$38K 0.01%
182
– –
MNTA
73
PUT
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$35K 0.01%
+2,500
New +$33.8K
AVEO
74
CALL
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$33K 0.01%
+1,200
New +$37.3K
AXDX
75
PUT
DELISTED
Accelerate Diagnostics
AXDX
– –
-6,000
Closed -$1.35M
1 2
3
4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2017 Portfolio in Review

As of Q4 2017, Acuta Capital Partners held 99 positions worth $530M, down 5.1% from $558M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Acuta Capital Partners withdrew a net $54.8M in Q4 2017, closing 25 positions and reducing 15 holdings. Its most notable exit was DBV Technologies, an estimated $8.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 47% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in AveXis, Inc. Common Stock worth $5.85M.

  • Acuta Capital Partners's largest Q4 2017 buy was AveXis, Inc. Common Stock: 52,900 shares worth $5.85M.
  • Acuta Capital Partners added most to Kadmon Holdings, Inc. in Q4 2017, an estimated $5.65M increase.
  • Acuta Capital Partners's biggest Q4 2017 reduction was Amicus Therapeutics, cutting an estimated $3.52M.
  • Acuta Capital Partners fully exited DBV Technologies in Q4 2017, selling an estimated $8.15M.
  • Acuta Capital Partners's ten largest holdings make up 67% of its $530M portfolio in Q4 2017.
  • Acuta Capital Partners opened 35 new positions and closed 25 in Q4 2017.
  • Acuta Capital Partners's portfolio value fell 5.1% quarter-over-quarter to $530M.

Based on Acuta Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.